3.96 0.00 (0.00%)
After hours: 6:25PM EDT
|Bid||3.90 x 3100|
|Ask||3.93 x 1000|
|Day's Range||3.80 - 3.96|
|52 Week Range||1.74 - 6.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
Matthew Cheslock joins Yahoo Finance from the floor of the New York Stock Exchange to discuss the latest market moves.
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Automatic ...
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
On a per-share basis, the Menlo Park, California-based company said it had a loss of 4 cents. The drugmaker posted revenue of $208,000 in the period. In the final minutes of trading on Tuesday, the company's ...
MENLO PARK, Calif., July 31, 2018-- Geron Corporation today reported financial results for the three and six months ended June 30, 2018.. Second Quarter and Year to Date 2018 Results. For the second quarter ...
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Geron Corporation (NASDAQ: GERN ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. To ...
HENDERSON NV / ACCESSWIRE / July 30, 2018 / In recent weeks, several biotech companies have released positive news around Q2 financials, and several are set to release updates this week. Making it a sector ...
Geron Corporation (GERN) today announced that it will release its second quarter 2018 financial results after the market closes on Tuesday, July 31, 2018. Geron will host a conference call to discuss the second quarter results and recent events at 4:30 p.m. ET the same day. Geron is a clinical stage biopharmaceutical company focused on collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
July 17 (Reuters) - Geron Co Ltd: * SAYS UNIT TO INVEST 283.0 MILLION YUAN ($42.35 million) IN STAINLESS STEEL PLATE PROJECT Source text in Chinese: https://bit.ly/2uGwvZt Further company coverage: ($1 ...
HENDERSON, NV / ACCESSWIRE / July 8, 2018 / In order to take a drug to market the cost was estimated to be $2.4 billion. This has caused many biotech firms to enter the device market, rather than drug ...
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...
IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent. Its primary efficacy endpoint is planned to be the rate of RBC-TI (red blood cell transfusion independence) for at least eight weeks. Key secondary endpoints are to be RBC-TI rates for 24 weeks, the amount of and changes in red blood cell transfusions, and hematologic improvement.
In August 2015, Geron (GERN) entered into a market issuance sales agreement with MLV, under which Geron could issue and sell its common stock for up to $50 million. Under the agreement, in Q1 2018, Geron sold ~776,800 shares of its common stock for net proceeds of ~$1.6 million. Geron entered into a collaboration and licensing agreement with Janssen Biotech in November 2014.
IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor. The primary endpoints for the trial are the spleen and symptom response rates. The secondary endpoints of the trial include safety and overall survival. Geron expects an overall survival assessment to provide key information for the imetelstat program for potential future clinical trials. The drug’s safety profile was found to be consistent with prior clinical trials focusing on hematologic malignancies.
Its interest expenses fell YoY (year-over-year) to $18,000 from $21,000, and its net loss was stable YoY, growing slightly to ~$7.19 million from $7.18 million. Its net loss per share improved YoY, shrinking to $0.04 from $0.05. In Q1 2018, Geron’s cash outflow from operating activities rose YoY to $7.37 million from $7.31 million. Its current ratio, which measures how effectively it can meet its short-term obligations, improved YoY to 20.8 from 9.
In collaboration with Janssen Biotech, biopharmaceutical company Geron (GERN) is currently supporting the clinical development of imetelstat for hematologic myeloid malignancies. Early clinical data for the drug suggests it may have disease-modifying activity by inhibiting progenitor cells of malignant clones for myelofibrosis, myelodysplastic syndromes, and essential thrombocythemia. The sole analyst covering Geron recommends “hold.” In April, there were three analysts covering the stock, of which one recommended “buy,” and two recommended “hold.” Their target price was $5.50.